Brought to you by 
Series C for CNS drug discovery firm EnVivo brings in $24mm
11 Oct 2006
Executive Summary
EnVivo Pharmaceuticals, which is developing small-molecule drug candidates for neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's, and spinocerebellar ataxias, raised $24mm in a Series C financing led by Fidelity Biosciences. The money will allow the company to enter its first compound, an alpha-7 nicotinic acetylcholine receptor agonist for AD in-licensed from Bayer HealthCare, into clinical trials this year.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C for CNS drug discovery firm EnVivo brings in $24mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice